ITMI970939A0 - - Google Patents

Info

Publication number
ITMI970939A0
ITMI970939A0 ITMI970939A ITMI970939A ITMI970939A0 IT MI970939 A0 ITMI970939 A0 IT MI970939A0 IT MI970939 A ITMI970939 A IT MI970939A IT MI970939 A ITMI970939 A IT MI970939A IT MI970939 A0 ITMI970939 A0 IT MI970939A0
Authority
IT
Italy
Application number
ITMI970939A
Other languages
Italian (it)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ITMI970939A0 publication Critical patent/ITMI970939A0/it
Priority to IT97MI000939A priority Critical patent/IT1291633B1/it
Priority to US09/403,524 priority patent/US6359001B1/en
Priority to DK98924164T priority patent/DK0977575T3/da
Priority to IL13250398A priority patent/IL132503A/en
Priority to CA002287887A priority patent/CA2287887A1/en
Priority to PCT/EP1998/002365 priority patent/WO1998047515A1/en
Priority to ES98924164T priority patent/ES2187028T3/es
Priority to PL98336386A priority patent/PL189304B1/pl
Priority to SK1424-99A priority patent/SK284255B6/sk
Priority to JP54502598A priority patent/JP2001521540A/ja
Priority to PT98924164T priority patent/PT977575E/pt
Priority to SI9830312T priority patent/SI0977575T1/xx
Priority to HU0002100A priority patent/HUP0002100A3/hu
Priority to AT98924164T priority patent/ATE227577T1/de
Priority to EP98924164A priority patent/EP0977575B1/en
Priority to NZ500435A priority patent/NZ500435A/en
Priority to AU76462/98A priority patent/AU732046B2/en
Priority to DE69809408T priority patent/DE69809408T2/de
Priority to CN98804999A priority patent/CN1255064A/zh
Priority to RU99124771/14A priority patent/RU2218159C2/ru
Priority to KR1019997009782A priority patent/KR20010020202A/ko
Publication of ITMI970939A1 publication Critical patent/ITMI970939A1/it
Application granted granted Critical
Publication of IT1291633B1 publication Critical patent/IT1291633B1/it
Priority to NO995122A priority patent/NO995122L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT97MI000939A 1997-04-22 1997-04-22 Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride IT1291633B1 (it)

Priority Applications (22)

Application Number Priority Date Filing Date Title
IT97MI000939A IT1291633B1 (it) 1997-04-22 1997-04-22 Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride
PT98924164T PT977575E (pt) 1997-04-22 1998-04-21 Utilizacao de alfa-metil-p-tirosina para inibir a producao de melanina nos melanocitos da iris
HU0002100A HUP0002100A3 (en) 1997-04-22 1998-04-21 The use of alpha-methyl-p-tyrosine to inhibit melanin production in iris melanocytes
IL13250398A IL132503A (en) 1997-04-22 1998-04-21 The use of tyrosine inhibitors in the preparation of a drug that prevents the production of melanin in the melanocytes of the iris, which is caused by prostaglandin derivatives
CA002287887A CA2287887A1 (en) 1997-04-22 1998-04-21 The use of .alpha.-methyl-p-tyrosine to inhibit melanin production in iris melanocytes
PCT/EP1998/002365 WO1998047515A1 (en) 1997-04-22 1998-04-21 THE USE OF α-METHYL-P-TYROSINE TO INHIBIT MELANIN PRODUCTION IN IRIS MELANOCYTES
ES98924164T ES2187028T3 (es) 1997-04-22 1998-04-21 El uso de alfa-metil-p-tirosina para inhibir la produccion de melanina en melanocitos de iris.
PL98336386A PL189304B1 (pl) 1997-04-22 1998-04-21 Zastosowanie alfa-metylo-p-tyrozyny do wytwarzania środka farmaceutycznego i kompozycja farmaceutyczna zawierająca alfa-metylo-p-tyrozynę
SK1424-99A SK284255B6 (sk) 1997-04-22 1998-04-21 Použitie alfa-metyl-p-tyrozínu na inhibíciu produkcie melanínu v melanocytoch dúhovky
JP54502598A JP2001521540A (ja) 1997-04-22 1998-04-21 虹彩メラノサイトにおけるメラニン生成を阻害するα−メチル−Ｐ−チロシンの使用
US09/403,524 US6359001B1 (en) 1997-04-22 1998-04-21 Use of α-methyl-p-tyrosine to inhibit melanin production in iris melanocytes
SI9830312T SI0977575T1 (en) 1997-04-22 1998-04-21 The use of alpha-methyl-p-tyrosine to inhibit melanin production in iris melanocytes
DK98924164T DK0977575T3 (da) 1997-04-22 1998-04-21 Anvendelse af alfa-methyl-p-tyrosin til inhibering af melaninproduktion i irismelanocytter
AT98924164T ATE227577T1 (de) 1997-04-22 1998-04-21 Anwendung von alpha-methyl-p-tyrosine zur hemmung der melanin-produktion in irismelanozyten
EP98924164A EP0977575B1 (en) 1997-04-22 1998-04-21 The use of alpha-methyl-p-tyrosine to inhibit melanin production in iris melanocytes
NZ500435A NZ500435A (en) 1997-04-22 1998-04-21 The use of alpha-methyl-p-tyrosine to inhibit melanin production in iris melanocytes
AU76462/98A AU732046B2 (en) 1997-04-22 1998-04-21 The use of alpha-methyl-p-tyrosine to inhibit melanin production in iris melanocytes
DE69809408T DE69809408T2 (de) 1997-04-22 1998-04-21 Anwendung von alpha-methyl-p-tyrosine zur hemmung der melanin-produktion in irismelanozyten
CN98804999A CN1255064A (zh) 1997-04-22 1998-04-21 α－甲基－对－酪氨酸抑制虹膜黑素细胞中黑色素的产生的用途
RU99124771/14A RU2218159C2 (ru) 1997-04-22 1998-04-21 ПРИМЕНЕНИЕ α-МЕТИЛ-п-ТИРОЗИНА ДЛЯ ИНГИБИРОВАНИЯ ПРОДУЦИРОВАНИЯ МЕЛАНИНА В МЕЛАНОЦИТАХ РАДУЖНОЙ ОБОЛОЧКИ
KR1019997009782A KR20010020202A (ko) 1997-04-22 1998-04-21 홍채 멜라닌세포에서의 멜라닌 생성을 억제하기 위한 α-메틸-Ｐ-티로신의 용도
NO995122A NO995122L (no) 1997-04-22 1999-10-21 Anvendelse av <alfa>-metyl-p-tyrosin for å inhibere melaninproduksjon i irismelanocytter

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97MI000939A IT1291633B1 (it) 1997-04-22 1997-04-22 Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride

Publications (3)

Publication Number Publication Date
ITMI970939A0 true ITMI970939A0 (en:Method) 1997-04-22
ITMI970939A1 ITMI970939A1 (it) 1998-10-22
IT1291633B1 IT1291633B1 (it) 1999-01-11

Family

ID=11376994

Family Applications (1)

Application Number Title Priority Date Filing Date
IT97MI000939A IT1291633B1 (it) 1997-04-22 1997-04-22 Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride

Country Status (22)

Country Link
US (1) US6359001B1 (en:Method)
EP (1) EP0977575B1 (en:Method)
JP (1) JP2001521540A (en:Method)
KR (1) KR20010020202A (en:Method)
CN (1) CN1255064A (en:Method)
AT (1) ATE227577T1 (en:Method)
AU (1) AU732046B2 (en:Method)
CA (1) CA2287887A1 (en:Method)
DE (1) DE69809408T2 (en:Method)
DK (1) DK0977575T3 (en:Method)
ES (1) ES2187028T3 (en:Method)
HU (1) HUP0002100A3 (en:Method)
IL (1) IL132503A (en:Method)
IT (1) IT1291633B1 (en:Method)
NO (1) NO995122L (en:Method)
NZ (1) NZ500435A (en:Method)
PL (1) PL189304B1 (en:Method)
PT (1) PT977575E (en:Method)
RU (1) RU2218159C2 (en:Method)
SI (1) SI0977575T1 (en:Method)
SK (1) SK284255B6 (en:Method)
WO (1) WO1998047515A1 (en:Method)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051980A1 (en) 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
WO2010087983A1 (en) * 2009-01-29 2010-08-05 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
US9744237B2 (en) * 2009-01-29 2017-08-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
US20120076848A1 (en) * 2009-07-22 2012-03-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
HRP20190046T1 (hr) * 2012-01-17 2019-05-03 Tyme, Inc. Kombinirana terapija za liječenje raka
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US9763903B2 (en) 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
ES2738248B2 (es) * 2018-06-21 2023-03-10 Consejo Superior Investigacion Uso de inhibidores de la tirosina hidroxilasa para el tratamiento del aneurisma de aorta
JP2021530568A (ja) 2018-07-19 2021-11-11 ヤモ・ファーマシューティカルズ・エルエルシー 自閉症を処置するための組成物および方法
WO2020232227A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
CN116035151A (zh) * 2023-01-18 2023-05-02 云南贝泰妮生物科技集团股份有限公司 一种刺梨闪释粉及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04117313A (ja) * 1990-09-06 1992-04-17 Kanebo Ltd 美白化粧料

Also Published As

Publication number Publication date
EP0977575B1 (en) 2002-11-13
NZ500435A (en) 2001-09-28
IT1291633B1 (it) 1999-01-11
NO995122L (no) 1999-12-21
PL336386A1 (en) 2000-06-19
HUP0002100A2 (hu) 2000-11-28
HUP0002100A3 (en) 2003-05-28
DK0977575T3 (da) 2003-03-10
SI0977575T1 (en) 2003-04-30
KR20010020202A (ko) 2001-03-15
IL132503A0 (en) 2001-03-19
RU2218159C2 (ru) 2003-12-10
AU732046B2 (en) 2001-04-12
PL189304B1 (pl) 2005-07-29
ES2187028T3 (es) 2003-05-16
PT977575E (pt) 2003-03-31
SK284255B6 (sk) 2004-12-01
IL132503A (en) 2004-06-20
SK142499A3 (en) 2000-09-12
WO1998047515A1 (en) 1998-10-29
DE69809408D1 (de) 2002-12-19
CN1255064A (zh) 2000-05-31
ITMI970939A1 (it) 1998-10-22
AU7646298A (en) 1998-11-13
JP2001521540A (ja) 2001-11-06
NO995122D0 (no) 1999-10-21
DE69809408T2 (de) 2003-07-10
ATE227577T1 (de) 2002-11-15
CA2287887A1 (en) 1998-10-29
EP0977575A1 (en) 2000-02-09
US6359001B1 (en) 2002-03-19

Similar Documents

Publication Publication Date Title
BE2018C032I2 (en:Method)
CH0944937H2 (en:Method)
ITMI970939A0 (en:Method)
ITTO970481A0 (en:Method)
ITMI971079A0 (en:Method)
ITTO970426A0 (en:Method)
BE2013C047I2 (en:Method)
ITMI971095A0 (en:Method)
ITUD970096A0 (en:Method)
IN184740B (en:Method)
IN188978B (en:Method)
IN189822B (en:Method)
IN191832B (en:Method)
ITCT970014V0 (en:Method)
ITGE970050A0 (en:Method)
ITMI971193A0 (en:Method)
ITMI971474A0 (en:Method)
ITRG970006A0 (en:Method)
ITRM970145V0 (en:Method)
CN3058269S (en:Method)
CN3057976S (en:Method)
CN3057730S (en:Method)
CN3055713S (en:Method)
CN3056209S (en:Method)
CN3058088S (en:Method)

Legal Events

Date Code Title Description
0001 Granted